CARBOPROST TROMETHAMINE INJECTION USP SOLUTION

ประเทศ: แคนาดา

ภาษา: อังกฤษ

แหล่งที่มา: Health Canada

สารออกฤทธิ์:

CARBOPROST (CARBOPROST TROMETHAMINE)

มีจำหน่ายจาก:

JUNO PHARMACEUTICALS CORP.

รหัส ATC:

G02AD04

INN (ชื่อสากล):

CARBOPROST

ปริมาณ:

250MCG

แบบฟอร์มเภสัชกรรม:

SOLUTION

องค์ประกอบ:

CARBOPROST (CARBOPROST TROMETHAMINE) 250MCG

เส้นทางการบริหาร:

INTRAMUSCULAR

หน่วยในแพ็คเกจ:

15G/50G

ประเภทใบสั่งยา:

Prescription

สรุปสินค้า:

Active ingredient group (AIG) number: 0133100001; AHFS:

สถานะการอนุญาต:

APPROVED

วันที่อนุญาต:

2023-05-26

สรุปลักษณะสินค้า

HOW TO STORE IT
PRODUCT MONOGRAPH
PR
CARBOPROST TROMETHAMINE INJECTION USP
250 mcg/mL carboprost (as carboprost tromethamine)
PROSTAGLANDIN
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, ON L5N 2X7
Date of Initial Authorization:
May 8, 2023
Date of Revision:
May 25, 2023
CONTROL NO. 265917
_` _
_ _
_Page 2 of 23 _
HOW TO STORE IT
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................ 3
SUMMARY OF PRODUCT INFORMATION
.................................................... 3
INDICATIONS AND CLINICAL USE
................................................................ 3
CONTRAINDICATIONS
......................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................... 4
ADVERSE REACTIONS
......................................................................................
7
DRUG INTERACTIONS
......................................................................................
9
DOSAGE AND ADMINISTRATION
.................................................................. 9
OVERDOSAGE
...................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................... 11
STORAGE AND STABILITY
............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................... 12
PART II: SCIENTIFIC INFORMATION
.................................................................. 13
PHARMACEUTICAL INFORMATION
............................................................ 13
DETAILED PHARMACOLOGY
.......................................................................
14
TOXICOLOGY
....................................................................................................
16
REFERENCES
.....................................................................................................
19
PART